Analisis Biaya dan Luaran Klinis Sindrom Koroner Akut Berbasis Clinical Pathway

https://doi.org/10.22146/jmpf.51176

Susan Fitria Candradewi(1*), Dyah Aryani Perwitasari(2), Nabilah Nabilah(3)

(1) Universitas Ahmad Dahlan
(2) Universitas Ahmad Dahlan
(3) Universitas Ahmad Dahlan
(*) Corresponding Author

Abstract


Health clinicians often show different variations in the choice of therapy they prescribe for patients depending on their expertise, knowledge, and even their art. This is likely to affect several things, including the cost that patients have to pay. Such a difference in costs is avoidable by applying scientific evidence-based medical service standards and having measurable outcomes known as Clinical Pathways. A clinical pathway serves as a tool to measure the quality of health services based on the standardization of the treatment process. This research was designed to determine the cost analysis of treatments received by patients with acute coronary syndrome (ACS) according to the clinical pathway. This non-experimental research employed a retrospective cohort study design. The data were gathered from the medical records of ACS patients who were treated at the ICCU of PKU Muhammadiyah Hospital in Yogyakarta, and the costs incurred were compared between treatments that matched and did not match the clinical pathways. The inclusion criteria were ACS patients treated during 2016 who were between ≥ 18 and <75 years old and had complete data. Meanwhile, the exclusion criteria were ACS patients who had incomplete data, tumor malignancy, and a creatinine level of > 3 mg/dL. Here, therapies given to patients are concluded to fit the clinical pathway if they are precisely the same (100%) as the Clinical Practice Guide used by this hospital. The clinical outcome was measured from the patient’s length of stay (LOS). During the data analysis, the costs of ACS patient treatments that were compliant and non-compliant with the clinical pathway were compared based on the level of severity using the Mann-Whitney test in the SPSS program. The results showed that of the 63 patients, 31 received treatments according to the clinical pathway, while the other 32 did not. The average LOS of the former and the latter were, respectively, 4.45 and 5.53 (p= 0.043), with the total costs of treatments up to IDR5,474,001,73 and IDR6,728,153.13 (p= 0,154). Conformity to a clinical pathway significantly influences the length of stay but does not affect the cost of care for acute coronary syndrome patients.


Full Text:

PDF


References

 

  1. Kementrian Kesehatan. Pharmaceutical Care Penyakit Cardiovascular. Jakarta: Direktur Bina Farmasi Komunitas dan Klinik, Kementrian Kesehatan RI; 2006.
  2. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: Executive Summary. Vol 130.; 2014. doi:10.1161/CIR.0000000000000133
  3. Cheah J. Clinical pathways - An evaluation of its impact on the quality of care in an acute care general hospital in Singapore. Singapore Med J. 2000;41(7):335-346.
  4. Rotter T, Kinsman L, James E, et al. The Effects of Clinical Pathways on Professional Practice, Patient Outcomes, Length of Stay, and Hospital Costs. Eval Health Prof. 2011;35(1):3-27. doi:10.1177/0163278711407313
  5. Pahriyani A, Andayani TM, Pramantara IDP. Pengaruh Implementasi Clinical Pathway Terhadap Luaran Klinik Dan Ekonomik Pasien Acute Coronary Syndrome. J Manaj dan Pelayanan Farm. 2014;4(September):146-150.
  6. Candradewi SF. ANALISIS EFEKTIVITAS DAN BIAYA ENOXAPARIN DIBANDINGKAN DENGAN FONDAPARINUX PADA PASIEN DENGAN SINDROM KORONER AKUT. 2015. https://repository.ugm.ac.id/134796/. Accessed April 13, 2019.
  7. Ariandiny M, Afriwardi A, Syafri M. Gambaran Tekanan Darah pada Pasien Sindrom Koroner Akut di RS Khusus Jantung Sumatera Barat Tahun 2011-2012. J Kesehat Andalas. 2014;3(2). http://jurnal.fk.unand.ac.id/index.php/jka/article/view/85. Accessed April 13, 2019.
  8. Susilo C. IDENTIFIKASI FAKTOR USIA, JENIS KELAMIN DENGAN LUAS INFARK MIOKARD PADA PENYAKIT JANTUNG KORONER (PJK) DI RUANG ICCU RSD DR. SOEBANDI JEMBER Cipto Susilo*. Indones J Heal Sci. 2015;6(1):1-7.
  9. Perhimpunan Dokter Spesialis Kardiovaskuler Indonesia. Panduan Praktik Klinis (PPK) Dan Clinical Pathway (CP) Penyakit Jantung Dan Pembuluh Darah.; 2016. http://www.inaheart.org/upload/file/Buku_PPK_CP_05Apr16.pdf.
  10. Siebens K, Miljoen H, Fieuws S, Drew B, De Geest S, Vrints C. Implementation of the guidelines for the management of patients with chest pain through a critical pathway approach improves length of stay and patient satisfaction but not anxiety. Crit Pathw Cardiol. 2010;9(1):30-34. doi:10.1097/HPC.0b013e3181d24549
  11. Huang D, Song X, Tian J, Cui Q, Yang K. Effects of clinical pathways in stroke management: A meta-analysis. Neurol Asia. 2015;20(4):335-342.
  12. Burgers PTPW, Lieshout EMM Van, Verhelst J, Dawson I, Rijcke PAR de. Implementing a clinical pathway for hip fractures; effects on hospital length of stay and complication rates in five hundred and twenty six patients. Int Orthop. 2014;38(5):1045. doi:10.1007/S00264-013-2218-5
  13. Busse R, Klazinga N, Pantell D, Quentin W. Improving Healthcare Quality in Europe. OECD; 2019. doi:10.1787/b11a6e8f-en
  14. Neubauer M. Clinical Pathways Can Lead to Cost Savings, Better Care.; 2014. https://www.onclive.com/view/clinical-pathways-can-lead-to-cost-savings-better-care#:~:text=Results of both of these,reduce costs by standardizing care.

 

 

 

 



DOI: https://doi.org/10.22146/jmpf.51176

Article Metrics

Abstract views : 802 | views : 28

Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats